肝病肌肉减少症发病机制研究进展

Pathogenesis of sarcopenia in liver diseases

目的肌肉减少症是指全身性肌肉质量降低和力量减退,机体生理功能障碍,并导致生活质量下降,甚至死亡的综合征,简称肌少症。肌少症可影响高达70%晚期肝病患者,与不良结局和预后相关。但目前大多数治疗以营养、运动等干预为主,尚缺乏疗效肯定的针对发病机制的治疗药物。本文总结了慢性肝病肌肉减少症的发病机制,以便确定治疗干预的靶点,改善临床预后。

Objective Sarcopenia is defined as loss of systemic skeletal muscle mass and functions.It may affect the physiological functions and leads to the declined quality of life,and even death.Sarcopenia occurs in up to 70%of patients with advanced liver diseases,which is associated with untoward clinical outcomes and poor prognosis.At present,most treatments are based on nutrition and exercise,however,there is still a lack of effective targeted molecular therapy.This review summarizes the pathogenesis of sarcopenia in liver diseases,in order to identify potential biomarkers for treatment and improve the clinical prognosis.